DiagnoCure Inc. reported earnings results for the fourth quarter 2013 and fiscal year ended October 31, 2013. The Corporation announced a net loss of $1,334,099 or $0.03 basic and diluted loss per share for the fourth quarter ended October 31, 2013, compared to $1,978,355 or $0.05 basic and diluted loss per share for the same period in 2012. Total revenues for the fourth quarter of 2013 were $149,465 compared to $142,995 for the same period of 2012. This increase of $6,470 is attributable to royalty revenues from Hologic Gen-Probe.

The Corporation announced a net loss of $3,566,942 or $0.08 basic and diluted loss per share for fiscal year 2013 compared to $3,679,324 or $0.09 basic and diluted loss per share for the same period in 2012. Total revenues for fiscal year 2013 were $671,228 compared with $2,472,038 for 2012. This decrease of $1,800,810 is attributable to the termination, on January 11, 2013 of the development and license agreements signed in June 2011 with Signal Genetics. That development agreement provided $1,223,485 of revenues in fiscal year 2012. The remaining decrease is attributable to the payment of $626,401 made by Gen-Probe in relation to the FDA milestone reached for PROGENSA(R) PCA3 in fiscal year 2012.